Genmab A/S (GMAB) News Today $20.80 -0.42 (-1.98%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Genmab A/S (NASDAQ:GMAB) Shares Gap Down - Here's What HappenedGenmab A/S (NASDAQ:GMAB) Shares Gap Down - Here's WhyJanuary 17 at 8:16 AM | marketbeat.comRep. Josh Gottheimer Sells Off Shares of Genmab A/S (NASDAQ:GMAB)January 17 at 4:25 AM | americanbankingnews.comGenmab A/S (NASDAQ:GMAB) Shares Gap Up - Still a Buy?Genmab A/S (NASDAQ:GMAB) Shares Gap Up - Still a Buy?January 16 at 10:38 AM | marketbeat.comGenmab A/S (NASDAQ:GMAB) Stock Unloaded Rep. Josh GottheimerRepresentative Josh Gottheimer (D-New Jersey) recently sold shares of Genmab A/S (NASDAQ:GMAB). In a filing disclosed on January 14th, the Representative disclosed that they had sold between $1,001 and $15,000 in Genmab A/S stock on December 16th. The trade occurred in the Representative's "MORGANJanuary 16 at 3:01 AM | marketbeat.comGenmab A/S (NASDAQ:GMAB) Given Consensus Rating of "Moderate Buy" by BrokeragesJanuary 14 at 2:43 AM | americanbankingnews.comGenmab A/S (NASDAQ:GMAB) Given Consensus Rating of "Moderate Buy" by AnalystsGenmab A/S (NASDAQ:GMAB - Get Free Report) has received an average rating of "Moderate Buy" from the ten research firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and six have assignedJanuary 14 at 2:42 AM | marketbeat.comTD Cowen Sticks to Their Hold Rating for Genmab (GMAB)January 8, 2025 | markets.businessinsider.comGenmab’s Strategic Positioning and Promising Clinical Data Drive Buy Rating with $50 Price TargetJanuary 8, 2025 | markets.businessinsider.comGenmab A/S's (GMAB) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $50.00 price target on shares of Genmab A/S in a report on Wednesday.January 8, 2025 | marketbeat.comGenmab to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 3, 2025 | globenewswire.comGenmab A/S (NASDAQ:GMAB) Trading 1.7% Higher - Still a Buy?Genmab A/S (NASDAQ:GMAB) Trading Up 1.7% - Here's What HappenedDecember 27, 2024 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Given Average Rating of "Moderate Buy" by BrokeragesShares of Genmab A/S (NASDAQ:GMAB - Get Free Report) have received an average recommendation of "Moderate Buy" from the nine research firms that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendaDecember 20, 2024 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Shares Gap Up - Time to Buy?Genmab A/S (NASDAQ:GMAB) Shares Gap Up - Still a Buy?December 18, 2024 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Short Interest Down 11.4% in NovemberGenmab A/S (NASDAQ:GMAB - Get Free Report) saw a large decrease in short interest in the month of November. As of November 30th, there was short interest totalling 2,020,000 shares, a decrease of 11.4% from the November 15th total of 2,280,000 shares. Based on an average daily volume of 1,150,000 shares, the days-to-cover ratio is currently 1.8 days. Approximately 0.3% of the company's stock are sold short.December 17, 2024 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Reaches New 52-Week Low - What's Next?Genmab A/S (NASDAQ:GMAB) Sets New 12-Month Low - Time to Sell?December 13, 2024 | marketbeat.comFmr LLC Has $6.78 Million Holdings in Genmab A/S (NASDAQ:GMAB)Fmr LLC raised its holdings in Genmab A/S (NASDAQ:GMAB - Free Report) by 13.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 278,194 shares of the company's stock after acquiring an additional 33,076 shaDecember 13, 2024 | marketbeat.comGenmab to Hold 2024 R&D Update and ASH Data Review MeetingDecember 11, 2024 | globenewswire.comVerition Fund Management LLC Purchases Shares of 29,074 Genmab A/S (NASDAQ:GMAB)Verition Fund Management LLC purchased a new position in Genmab A/S (NASDAQ:GMAB - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 29,074 shares of the company's stock, valued at approximately $7December 10, 2024 | marketbeat.comTwo Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)December 9, 2024 | businesswire.comTwo Sigma Advisers LP Buys 280,900 Shares of Genmab A/S (NASDAQ:GMAB)Two Sigma Advisers LP lifted its stake in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 84.1% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 615,100 shares of the company's stock after purchasing an additional 280,900 shares durinDecember 9, 2024 | marketbeat.comGenmab : Epcoritamab Combo Shows High Response Rates In 1b/2 Trial For R/R Follicular LymphomaDecember 8, 2024 | markets.businessinsider.comInvestigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary AnalysisDecember 8, 2024 | businesswire.comGenmab Is Too Attractive To IgnoreDecember 8, 2024 | seekingalpha.comInvestigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)December 7, 2024 | businesswire.comCapital Increase in Genmab as a Result of Employee Warrant ExerciseDecember 3, 2024 | globenewswire.comTransactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated PersonsDecember 3, 2024 | globenewswire.comWhy Is Genmab A/S (GMAB) Among the Worst Performing Healthcare Stocks in 2024?November 27, 2024 | msn.comGenmab to Present at Citi's Global Healthcare ConferenceNovember 25, 2024 | globenewswire.comNatixis Advisors LLC Grows Stake in Genmab A/S (NASDAQ:GMAB)Natixis Advisors LLC lifted its stake in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 29.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 206,563 shares of the company's stock after buying an additional 47,437 shares dNovember 23, 2024 | marketbeat.comGrant of Restricted Stock Units and Warrants to Employees in GenmabNovember 21, 2024 | globenewswire.comGenmab A/S (NASDAQ:GMAB) Sets New 1-Year Low - Should You Sell?Genmab A/S (NASDAQ:GMAB) Hits New 52-Week Low - Here's WhyNovember 19, 2024 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Short Interest UpdateGenmab A/S (NASDAQ:GMAB - Get Free Report) was the target of a significant growth in short interest in October. As of October 31st, there was short interest totalling 2,340,000 shares, a growth of 23.2% from the October 15th total of 1,900,000 shares. Based on an average trading volume of 874,600 shares, the short-interest ratio is currently 2.7 days. Approximately 0.4% of the company's stock are short sold.November 17, 2024 | marketbeat.comGenmab A/S (GMAB): Among 12 High Growth Large Cap Stocks to Buy NowNovember 15, 2024 | msn.comCrossmark Global Holdings Inc. Has $932,000 Stake in Genmab A/S (NASDAQ:GMAB)Crossmark Global Holdings Inc. reduced its stake in Genmab A/S (NASDAQ:GMAB - Free Report) by 45.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 38,245 shares of the company's stock after selling 32,387 sharesNovember 15, 2024 | marketbeat.comLeerink Partnrs Forecasts Increased Earnings for Genmab A/SGenmab A/S (NASDAQ:GMAB - Free Report) - Stock analysts at Leerink Partnrs upped their FY2024 earnings per share estimates for Genmab A/S in a report issued on Wednesday, November 6th. Leerink Partnrs analyst J. Chang now expects that the company will earn $1.29 per share for the year, up from thNovember 11, 2024 | marketbeat.comGenmab A/S (GMAB) Q3 2024 Earnings Conference Call TranscriptNovember 9, 2024 | seekingalpha.comGenmab A/S 2024 Q3 - Results - Earnings Call PresentationNovember 9, 2024 | seekingalpha.comGenmab A/S (NASDAQ:GMAB) Receives "Outperform" Rating from BMO Capital MarketsBMO Capital Markets reaffirmed an "outperform" rating and set a $48.00 price objective (up from $46.00) on shares of Genmab A/S in a report on Friday.November 8, 2024 | marketbeat.comFY2024 EPS Estimates for Genmab A/S Boosted by William BlairGenmab A/S (NASDAQ:GMAB - Free Report) - Equities research analysts at William Blair upped their FY2024 earnings per share estimates for Genmab A/S in a report issued on Wednesday, November 6th. William Blair analyst M. Phipps now anticipates that the company will post earnings of $1.24 per shareNovember 8, 2024 | marketbeat.comGenmab’s Revenue Soars with Strategic DevelopmentsNovember 7, 2024 | markets.businessinsider.comGenmab A/S: Genmab Announces Financial Results for the First Nine Months of 2024November 6, 2024 | finanznachrichten.deGenmab Revenue Surges 18% in Q3November 6, 2024 | fool.comGenmab Announces Financial Results for the First Nine Months of 2024November 6, 2024 | globenewswire.comGenmab: Looking To Manage My Position Around Q3 EarningsNovember 6, 2024 | seekingalpha.comGenmab A/S (NASDAQ:GMAB) Sees Strong Trading Volume - Should You Buy?Genmab A/S (NASDAQ:GMAB) Sees Large Volume Increase - Time to Buy?November 5, 2024 | marketbeat.comGenmab to Present at Jefferies London Healthcare ConferenceNovember 5, 2024 | globenewswire.comGenmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual MeetingNovember 5, 2024 | businesswire.comGenmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual MeetingNovember 5, 2024 | globenewswire.comUS Bancorp DE Has $4.19 Million Holdings in Genmab A/S (NASDAQ:GMAB)US Bancorp DE boosted its holdings in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 16.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 171,669 shares of the company's stock after buying an aNovember 5, 2024 | marketbeat.comCreative Planning Purchases 27,353 Shares of Genmab A/S (NASDAQ:GMAB)Creative Planning raised its position in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 136.3% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 47,422 shares of the company's stock after purchasing an additional 27,353 shaNovember 1, 2024 | marketbeat.com Get Genmab A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for GMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address GMAB Media Mentions By Week GMAB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GMAB News Sentiment▼0.960.72▲Average Medical News Sentiment GMAB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GMAB Articles This Week▼75▲GMAB Articles Average Week Get Genmab A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for GMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Takeda Pharmaceutical News Today argenx News Today BioNTech News Today Teva Pharmaceutical Industries News Today BeiGene News Today Viatris News Today Intra-Cellular Therapies News Today Moderna News Today Summit Therapeutics News Today Dr. Reddy's Laboratories News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GMAB) was last updated on 1/17/2025 by MarketBeat.com Staff From Our PartnersI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genmab A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Genmab A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GMAB Stock Alerts